GE91.F GENMAB AS SP.ADR/1/10DK 1
- Market cap
- EUR 29.8B
- P/E
- 47.9x
- P/B
- 5.24x
- ROE
- 14.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GE91.F undervalued?
Graham numberThe Graham number of GENMAB AS SP.ADR/1/10DK 1 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENMAB AS SP.ADR/1/10DK 1 fundamental analysis
No fundamental analysis for GENMAB AS SP.ADR/1/10DK 1 yet.
GENMAB AS SP.ADR/1/10DK 1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…
Full company profileGENMAB AS SP.ADR/1/10DK 1 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GENMAB AS SP.ADR/1/10DK 1 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.28B | 2.09B | 2.39B | 3.12B | 3.72B | 4.32B |
| Gross Profit | 1.28B | 2.09B | 2.36B | 2.98B | 3.48B | 4.00B |
| Operating Income | 450M | 902M | 772M | 1.02B | 1.25B | 1.43B |
| EBITDA | - | 1.06B | 870M | 1.40B | 1.34B | 1.52B |
| Net Income | 450M | 785M | 631M | 1.13B | 963M | 931M |
| EPS | 6.85 | 12 | 9.66 | 18 | 16 | 15 |
| Balance Sheet | ||||||
| Total Assets | 3.75B | 4.33B | 5.24B | 6.39B | 12.9B | 12.9B |
| Total Liabilities | 370M | 408M | 546M | 1.27B | 7.03B | 6.60B |
| Shareholders' Equity | 3.38B | 3.93B | 4.69B | 5.12B | 5.85B | 6.33B |
| Cash & Short-term Investments | 1.36B | 1.42B | 2.21B | 1.38B | 1.72B | 1.86B |
| Cash Flow | ||||||
| Operating Cash Flow | 339M | 563M | 1.10B | 1.08B | 1.19B | 765M |
| Capital Expenditure | 38.4M | 45.6M | 55.8M | 42.4M | 55.0M | 25.3M |
| Free Cash Flow | 301M | 517M | 1.04B | 1.04B | 1.13B | 740M |
| Ratios | ||||||
| ROE | 13.3% | 20.0% | 13.4% | 22.1% | 16.5% | 14.7% |
| ROA | 12.0% | 18.1% | 12.0% | 17.7% | 7.5% | 7.2% |
| Net Profit Margin | 35.1% | 37.6% | 26.4% | 36.3% | 25.9% | 21.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENMAB AS SP.ADR/1/10DK 1 dividends
GENMAB AS SP.ADR/1/10DK 1 has not paid dividends in the last 5 fiscal years.
Who owns GENMAB AS SP.ADR/1/10DK 1
- Insiders 0.00%
- Institutions 20.57%
- Public & others 79.44%
- Shares outstanding 617M
- Free float 589M
GENMAB AS SP.ADR/1/10DK 1 company profile
- Company name
- GENMAB AS SP.ADR/1/10DK 1
- Ticker
- GE91.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,244
- Fiscal year end
- December
- Address
- Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
- Phone
- 45 70 20 27 28
- Website
- genmab.com
About GENMAB AS SP.ADR/1/10DK 1
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
GENMAB AS SP.ADR/1/10DK 1 management
10- Dr. Jan G.J. van de Winkel Ph.D.Co-Founder, President & CEO · born 1961
- Mr. Anthony Pagano CPAExecutive VP & CFO · born 1978
- Mr. Rayne WallerExecutive VP & Chief Technical Operations Officer · born 1968
- Mr. Gregory David Emil MuellerExecutive VP, General Counsel & Chief Legal Officer · born 1971
- Mr. Christopher CozicExecutive VP & Chief People Officer · born 1978
- Dr. Martine J. van Vugt Ph.D.Executive VP & Chief Strategy Officer · born 1971
- Mr. Martin SchultzSenior Director, Head of Development Business Partnership & Strategy and Director · born 1975
- Dr. Judith V. Klimovsky M.D.Executive VP & Chief Development Officer · born 1958
- Dr. Tahamtan Ahmadi M.D., Ph.D.Executive VP, Chief Medical Officer & Head of Experimental Medicines · born 1973
- Dr. Mijke Zachariasse Ph.D.VP, Head of Antibody Research Materials & Director · born 1973